Managing Editor, In Vivo
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Lucie Ellis
Denali Therapeutics will pay around $470m in upfront and milestone payments to acquire its CNS bispecific antibody development partner F-star Gamma, lending credence to F-star’s business model of individual, asset-specific spin offs.
In the backlash following the failure of its late-stage amyloidosis drug, Prothena has announced it will cut 57% of its workforce as part of a restructuring plan.
Recent deal-making has seen new developments to further existing agreements, including Allergan licensing a depression candidate from the spinout of a company it bought in 2015. Also, updates on deals involving Celgene, AstraZeneca and Daiichi Sankyo.
Emerging Company Profile: Emergex Vaccines will use its nanobody technology to develop entirely synthetic immunizations against the world’s most concerning infectious diseases, including Ebola; evolving current options for vaccine stockpiling and national repositories.
After delays caused by two complete response letters, AstraZeneca’s Lokelma has been approved in the US with label benefits over its major competitor, Vifor Pharma’s Veltessa.
Tagrisso shines for AstraZeneca in the first quarter and the company is on track for approval of a fifth new cancer drug, in line with 2014 promises made by CEO Pascal Soriot when the company rejected takeover offers from Pfizer.